JP2006527740A - 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤 - Google Patents

白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤 Download PDF

Info

Publication number
JP2006527740A
JP2006527740A JP2006516230A JP2006516230A JP2006527740A JP 2006527740 A JP2006527740 A JP 2006527740A JP 2006516230 A JP2006516230 A JP 2006516230A JP 2006516230 A JP2006516230 A JP 2006516230A JP 2006527740 A JP2006527740 A JP 2006527740A
Authority
JP
Japan
Prior art keywords
peptide
integrin
prommp
domain
mmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006516230A
Other languages
English (en)
Japanese (ja)
Inventor
ステファニダキス，ミカエル
ビョルクルンド，ミカエル
コイヴネン，エルッキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTT Cancer Targeting Technologies Oy
Original Assignee
CTT Cancer Targeting Technologies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20030923A external-priority patent/FI20030923A7/fi
Priority claimed from FI20040616A external-priority patent/FI20040616A0/fi
Application filed by CTT Cancer Targeting Technologies Oy filed Critical CTT Cancer Targeting Technologies Oy
Publication of JP2006527740A publication Critical patent/JP2006527740A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2006516230A 2003-06-19 2004-06-21 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤 Withdrawn JP2006527740A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030923A FI20030923A7 (fi) 2003-06-19 2003-06-19 Leukosyytti-proMMP-9/beta2-integriinikompleksin inhibiittorit
FI20040616A FI20040616A0 (fi) 2004-04-29 2004-04-29 Solumigraation inhibiittorit
PCT/FI2004/000375 WO2004110477A1 (en) 2003-06-19 2004-06-21 Inhibitors of the leukocyte prommp-9/beta(2) integrin complex

Publications (1)

Publication Number Publication Date
JP2006527740A true JP2006527740A (ja) 2006-12-07

Family

ID=33553915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006516231A Withdrawn JP2006527741A (ja) 2003-06-19 2004-06-21 細胞遊走の阻害剤
JP2006516230A Withdrawn JP2006527740A (ja) 2003-06-19 2004-06-21 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006516231A Withdrawn JP2006527741A (ja) 2003-06-19 2004-06-21 細胞遊走の阻害剤

Country Status (3)

Country Link
EP (2) EP1644031A1 (enExample)
JP (2) JP2006527741A (enExample)
WO (2) WO2004110478A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1853624A2 (en) * 2005-01-31 2007-11-14 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic peptides derived from urokinase plasminogen activator receptor
WO2007020405A2 (en) * 2005-08-12 2007-02-22 Cartela R & D Ab Integrin i-domain binding peptides
GB2429012A (en) * 2005-08-12 2007-02-14 Cartela Ab Polypeptides capable of binding an integrin I-domain.
JP5749651B2 (ja) 2008-11-04 2015-07-15 インデックス・ファーマシューティカルズ・アクチエボラーグ 多形核細胞の動員および／または遊走を減少させる化合物および方法
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
US11466080B2 (en) 2017-03-22 2022-10-11 Children's Medical Center Corporation Methods of treating cancer using anti-LRP1 polyclonal antibodies
EP3600377A4 (en) 2017-03-22 2021-01-06 Children's Medical Center Corporation INHIBITION OF PRSS2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US20030022835A1 (en) * 1998-04-29 2003-01-30 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
GB9809764D0 (en) * 1998-05-07 1998-07-08 Isis Innovation MMP-9 Gene polymorphisms
ES2327812T3 (es) * 1999-07-13 2009-11-04 University Of Southern California Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7034134B2 (en) * 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
EP1578918A2 (en) * 2002-04-23 2005-09-28 Duke University Atherosclerotic phenotype determinative genes and methods for using the same

Also Published As

Publication number Publication date
JP2006527741A (ja) 2006-12-07
EP1644032A1 (en) 2006-04-12
EP1644031A1 (en) 2006-04-12
WO2004110478A1 (en) 2004-12-23
WO2004110477A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
Wright et al. Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen.
Wachtfogel et al. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5).
US6201104B1 (en) Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
Stefanidakis et al. Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte β2 integrins
US7935785B2 (en) Selective substrates for matrix metalloproteinases
HU225326B1 (en) Integrin binding peptide and use thereof
RU2260599C2 (ru) МОДУЛЯТОР АГРЕГАЦИИ ПЕПТИДА β-АМИЛОИДА ДЛЯ ИНГИБИРОВАНИЯ АГРЕГАЦИИ ПЕПТИДОВ ПРИРОДНОГО β -АМИЛОИДА ИЛИ ДЛЯ ЛЕЧЕНИЯ СУБЪЕКТА ОТ НАРУШЕНИЯ, АССОЦИИРОВАННОГО С β -АМИЛОИДОЗОМ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ДЕТЕКЦИИ В БИОЛОГИЧЕСКОМ ОБРАЗЦЕ ПЕПТИДОВ ПРИРОДНОГО β -АМИЛОИДА
KR20170137929A (ko) 효소 활성화 인자 XII(FXIIa)의 신규한 저해제
CN102300987A (zh) 膜型-1基质金属蛋白抑制剂及其用途
WO1996023813A1 (en) Peptides and compounds that bind to sh2 domains
GB2453589A (en) Protease inhibition
CN103391787A (zh) uPAR拮抗剂及其应用
JP2006527740A (ja) 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤
Mesters et al. Generation of fusion proteins for selective occlusion of tumor vessels
US20070207967A1 (en) Peptide Inhibitors of Matrix Metalloproteinase Activity
US20020025510A1 (en) Screening methods based on superactivated alpha V beta 3 integrin
Goligorsky et al. Molecular mimicry of integrin ligation: therapeutic potential of arginine-glycine-aspartic acid (RGD) peptides.
AU774355B2 (en) Novel bag proteins and nucleic acid molecules encoding them
US6667388B2 (en) Peptide inhibitor of MMP activity and angiogenesis
US9133239B2 (en) Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration
WO2007048186A1 (en) Leukocyte-binding polypeptides and uses thereof
EP2843048A1 (en) NOVEL INTEGRIN alpha9beta1 LIGAND AND USES THEREOF
KR20030093238A (ko) 백혈구 인테그린의 신규 펩티드 리간드
JP2001518119A (ja) 細胞活性化の選択的阻害剤としてのブラジキニン類似体
WO2000027420A9 (en) Compositions and methods for treatment of cancer

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070904